Kennedy Capital Management LLC Takes $8.78 Million Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Kennedy Capital Management LLC bought a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,166,002 shares of the company’s stock, valued at approximately $8,780,000.

Several other hedge funds have also recently bought and sold shares of HCAT. Vanguard Group Inc. increased its holdings in Health Catalyst by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,441,707 shares of the company’s stock worth $65,190,000 after purchasing an additional 78,823 shares in the last quarter. Impax Asset Management Group plc grew its holdings in shares of Health Catalyst by 52.0% during the fourth quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company’s stock worth $16,246,000 after buying an additional 600,000 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in shares of Health Catalyst by 34.1% during the fourth quarter. Perigon Wealth Management LLC now owns 40,697 shares of the company’s stock worth $377,000 after buying an additional 10,355 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in Health Catalyst in the 4th quarter valued at approximately $172,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Health Catalyst by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock worth $140,000 after acquiring an additional 2,817 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Down 0.8 %

Shares of HCAT stock traded down $0.06 on Tuesday, reaching $7.63. The stock had a trading volume of 186,563 shares, compared to its average volume of 590,058. Health Catalyst, Inc. has a 12 month low of $5.45 and a 12 month high of $14.37. The firm has a market capitalization of $450.40 million, a price-to-earnings ratio of -4.12 and a beta of 1.32. The firm’s 50-day moving average is $6.62 and its two-hundred day moving average is $7.51.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The firm had revenue of $74.72 million for the quarter, compared to the consensus estimate of $74.81 million. On average, sell-side analysts forecast that Health Catalyst, Inc. will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HCAT. Wells Fargo & Company lowered their price objective on shares of Health Catalyst from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Evercore ISI lowered their price target on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 9th. Piper Sandler cut their price target on shares of Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a research report on Thursday, June 6th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of Health Catalyst in a report on Tuesday, May 21st. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Health Catalyst in a research report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.91.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 5,208 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total transaction of $32,029.20. Following the completion of the sale, the chief operating officer now owns 155,215 shares in the company, valued at approximately $954,572.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 8,564 shares of company stock worth $54,889. Company insiders own 2.70% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.